Bernard A. Fox
Dr. Bernard A. Fox received his Ph.D. from Wayne State University, Detroit, Michigan. His postgraduate training was with Dr. Steven A. Rosenberg, NCI, NIH. Prior to coming to Portland he was on the faculty at the University of Michigan Medical School. Since 1994 he has been Chief, Laboratory of Molecular and Tumor Immunology, at the Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Providence Portland Medical Center, Portland, Oregon. He is an Associate Professor, Molecular Microbiology and Immunology, Oregon Health and Science University and co-leader of the Tumor Immunology Focus Panel for the Knight Cancer Institute. Dr. Fox’s research efforts are divided between preclinical animal models, the development, performance and monitoring of immunotherapy trials for patients with cancer and the training of the next generation of translational investigators. He is currently involved with translational immunotherapy trials for patients with melanoma, prostate, breast and non-small cell lung cancer. He has served as a member of review committees for the NIH, FDA, philanthropic and governmental organizations in the USA, Europe and Asia, is on the editorial boards of six scientific journals, lectures widely, consults for the biotechnology/pharma sector and is an internationally recognized expert on cancer immunotherapy. A founding member of the Tumor Vaccine and Cell Therapy Working Group, Dr. Fox has coordinated their International meetings for the past 16 years. Dr. Fox is the Immediate Past President of the International Society for Biological Therapy of Cancer / Society for Immunotherapy of Cancer (iSBTc / SITC), serves on the Scientific Advisory Board of the Biological Development Association (Europe); The Hollings Cancer Center, Medical University of South Carolina; the Vaccine Branch, NCI, NIH; and is a co-founder of UbiVac, a biotech with novel cancer vaccine technology.
For information please contact email@example.com